These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27408930)

  • 41. A novel bioassay for the determination of neutralizing antibodies to IFN-beta1b.
    Pungor E; Files JG; Gabe JD; Do LT; Foley WP; Gray JL; Nelson JW; Nestaas E; Taylor JL; Grossberg SE
    J Interferon Cytokine Res; 1998 Dec; 18(12):1025-30. PubMed ID: 9877445
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
    Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. IFN-beta1a and IFN-beta1b have different patterns of influence on cytokines.
    Sega S; Wraber B; Mesec A; Horvat A; Ihan A
    Clin Neurol Neurosurg; 2004 Jun; 106(3):255-8. PubMed ID: 15177779
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosis.
    Dressel A; Kolb AK; Elitok E; Bitsch A; Bogumil T; Kitze B; Tumani H; Weber F
    Acta Neurol Scand; 2006 Dec; 114(6):368-73. PubMed ID: 17083335
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing-remitting multiple sclerosis (the ARIANNA study).
    Lanzillo R; Quarantelli M; Pozzilli C; Trojano M; Amato MP; Marrosu MG; Francia A; Florio C; Orefice G; Tedeschi G; Bellantonio P; Annunziata P; Grimaldi LM; Comerci M; Brunetti A; Bonavita V; Alfano B; Marini S; Brescia Morra V;
    Mult Scler; 2016 Aug; 22(9):1163-73. PubMed ID: 26466947
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thrombotic Microangiopathy Presenting with Intestinal Involvement Following Long-term Interferon-β1b Treatment for Multiple Sclerosis.
    Omoto S; Utsumi T; Matsuno H; Terasawa Y; Iguchi Y
    Intern Med; 2018 Mar; 57(5):741-744. PubMed ID: 29151517
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Type 1 IFN-induced protein MxA and plasmacytoid dendritic cells in lesions of morphea.
    Ghoreishi M; Vera Kellet C; Dutz JP
    Exp Dermatol; 2012 Jun; 21(6):417-9. PubMed ID: 22507598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing-remitting multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Saccà F; Russo CV; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2018 Jan; 19():50-54. PubMed ID: 29128737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
    Reder AT; Velichko S; Yamaguchi KD; Hamamcioglu K; Ku K; Beekman J; Wagner TC; Perez HD; Salamon H; Croze E
    J Interferon Cytokine Res; 2008 May; 28(5):317-31. PubMed ID: 18547162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arthritis during interferon beta-1b treatment in multiple sclerosis.
    Altintas A; Alici Y; Melikoğlu M; Siva A
    Mult Scler; 2002 Dec; 8(6):534-6. PubMed ID: 12474998
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4.
    Furlan R; Bergami A; Lang R; Brambilla E; Franciotta D; Martinelli V; Comi G; Panina P; Martino G
    J Neuroimmunol; 2000 Nov; 111(1-2):86-92. PubMed ID: 11063825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Healthcare resource utilization following switch or discontinuation in multiple sclerosis patients on disease modifying drugs.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    J Med Econ; 2010 Mar; 13(1):90-8. PubMed ID: 20078189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy.
    Jia H; Thelwell C; Dilger P; Bird C; Daniels S; Wadhwa M
    Thromb Res; 2018 Mar; 163():105-116. PubMed ID: 29407621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.
    Guillemin GJ; Kerr SJ; Pemberton LA; Smith DG; Smythe GA; Armati PJ; Brew BJ
    J Interferon Cytokine Res; 2001 Dec; 21(12):1097-101. PubMed ID: 11798468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interferon-beta: mechanism of action and dosing issues.
    Markowitz CE
    Neurology; 2007 Jun; 68(24 Suppl 4):S8-11. PubMed ID: 17562848
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Multiple sclerosis, interferon beta and clinical thyroid dysfunction.
    Kreisler A; de Seze J; Stojkovic T; Delisse B; Combelles M; Vérier A; Hautecoeur P; Vermersch P;
    Acta Neurol Scand; 2003 Feb; 107(2):154-7. PubMed ID: 12580868
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.